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Summary
The autosomal recessive neuromuscular disorder prox-
imal spinal muscular atrophy (SMA) is caused by the
loss or mutation of the survival motor neuron (SMN)
gene, which exists in two nearly identical copies, telo-
meric SMN (telSMN) and centromeric SMN (cenSMN).
Exon 7 of the telSMN gene is homozygously absent in
∼95% of SMA patients, whereas loss of cenSMN does
not cause SMA. We searched for other telSMN muta-
tions among 23 SMA compound heterozygotes, using
heteroduplex analysis. We identified telSMN mutations
in 11 of these unrelated SMA-like individuals who carry
a single copy of telSMN: these include two frameshift
mutations (800ins11 and 542delGT) and three missense
mutations (A2G, S262I, and T274I). The telSMN mu-
tations identified to date cluster at the 3′ end, in a region
containing sites for SMN oligomerization and binding
of Sm proteins. Interestingly, the novel A2G missense
mutation occurs outside this conserved carboxy-terminal
domain, closely upstream of an SIP1 (SMN-interacting
protein 1) binding site. In three patients, the A2G mu-
tation was found to be on the same allele as a rare
polymorphism in the 5′ UTR, providing evidence for a
founder chromosome; Ag1-CAmarker data also support
evidence of an ancestral origin for the 800ins11 and
542delGT mutations. We note that telSMN missense
mutations are associated with milder disease in our pa-
tients and that the severe type I SMA phenotype caused
by frameshift mutations can be ameliorated by an in-
crease in cenSMN gene copy number.
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Introduction
Proximal spinal muscular atrophy (SMA) is an auto-
somal recessive neuromuscular disorder characterizedby
destruction of a-motor neurons in the anterior horn of
the spinal cord. SMA has an estimated incidence of 1/
10,000 live births, with a carrier frequency of ∼1/50
individuals (Pearn 1980; Melki et al. 1994). Childhood-
onset SMA is classified into three groups, on the basis
of age at onset and clinical course (Munsat and Davies
1992). Type I SMA (Werdnig-Hoffmann disease; MIM
253300) is the most severe form, with onset at !6 mo
of age and death usually occurring by 2 years of age.
Type II SMA (MIM 253550) is of intermediate severity:
onset occurs at !18 mo of age, and patients never gain
the ability to walk. Type III SMA (Kugelberg-Welander
disease; MIM 253400) is the mildest form of the disease:
onset occurs at 118 mo of age, and patients are able to
both stand and walk on their own.
All three forms of childhood SMA have been mapped,
by linkage analysis, to chromosome 5q11.2-q13.3
(Brzustowicz et al. 1990; Melki et al. 1990; Daniels et
al. 1992; Simard et al. 1992; MacKenzie et al. 1993;
Brahe et al. 1994; Burghes et al. 1994a; Wirth et al.
1994, 1995), a region of complex genomic organization
that contains numerous repeated sequences, including
polymorphic markers and genes (Francis et al. 1993;
Kleyn et al. 1993; Carpten et al. 1994; Melki et al. 1994;
Lefebvre et al. 1995; Roy et al. 1995; Thompson et al.
1995). Three genes have been identified and character-
ized in the SMA critical region: the survival motor neu-
ron (SMN) gene (Lefebvre et al. 1995), the gene for
neuronal apoptosis inhibitory protein (Roy et al. 1995;
Thompson et al. 1995), and p44, a subunit of the gene
for the basal transcription factor TFIIH (Bu¨rglen et al.
1997; Carter et al. 1997).
The SMN gene is present in two nearly identical copies
on 5q, telomeric SMN (telSMN) and centromeric SMN
(cenSMN), which can be distinguished by single-base
changes in exons 7 and 8 (Lefebvre et al. 1995; van der
Steege et al. 1995). Exon 7 of the telSMN gene is not
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detectable in ∼95% of SMA patients, owing to either
deletion of telSMN or conversion of telSMN sequences
to cenSMN (Hahnen et al. 1995; Lefebvre et al. 1995;
Rodrigues et al. 1995; Hahnen et al. 1996; van der
Steege et al. 1996; Velasco et al. 1996; DiDonato et al.
1997). Loss of the cenSMN gene does not cause SMA;
however, increased cenSMN gene copy number, which
can occur as a result of gene conversion events from
telSMN to cenSMN, has been shown to be associated
with a milder SMA phenotype (Burghes 1997; Campbell
et al. 1997; DiDonato et al. 1997; McAndrew et al.
1997). The fact that exon 7 of the telSMN gene is ho-
mozygously absent in a large majority of SMA patients
has enabled the development of an effective PCR-based
assay for the molecular diagnosis of SMA (Lefebvre et
al. 1995; van der Steege et al. 1995). In addition, di-
agnosis of SMA carriers is now possible, by use of a
quantitative PCR-based assay for determination of
telSMN copy number (McAndrew et al. 1997). In SMA
patients who retain the telSMN gene, a limited number
of other intragenic telSMN mutations have been iden-
tified (Bussaglia et al. 1995; Lefebvre et al. 1995; Brahe
et al. 1996; Bu¨rglen et al. 1996b; Parsons et al. 1996,
1998; Hahnen et al. 1997; McAndrew et al. 1997; Roch-
ette et al. 1997; Talbot et al. 1997a), providing strong
evidence for confirmation of the role of the SMN gene
as the primary SMA-determining gene.
Both the cenSMN and telSMN genes have been tran-
scribed, and alternative splicing of these transcripts has
been demonstrated. The telSMN gene produces primar-
ily full-length SMN transcripts, whereas the cenSMN
gene produces more alternatively spliced isoforms (lack-
ing exons 5 and/or 7) and less full-length SMN tran-
scripts (Gennarelli et al. 1995; Lefebvre et al. 1995).
Only expression of full-length SMN transcripts can be
detected at the protein level. The reduction of SMN-
protein levels in SMA patients has been found to be
directly correlated with the severity of the SMA phe-
notype (Coovert et al. 1997; Lefebvre et al. 1997). The
detection of SMN protein in SMA patients who lack the
telSMN gene indicates that the cenSMN gene does pro-
duce protein, although in significantly lower amounts
than the telSMN gene.
Although several intragenic telSMN mutations have
been reported in SMA patients, a more comprehensive
survey of these mutations is essential for providing in-
sight into important structural and functional domains
of the SMN protein. Recent experiments have suggested
a role for the SMN protein in spliceosomal small nuclear
ribonucleoprotein (snRNP) biogenesis (Liu and Dreyfuss
1996; Fischer et al. 1997; Liu et al. 1997; Mattaj 1998),
but information regarding critical regions of the SMN
protein remains limited. Since ∼95% of SMA patients
are homozygously lacking the telSMN gene, the rela-
tively rare intragenic telSMN mutations are valuable for
defining these critical domains. In addition, these mu-
tations may help to further define the correlation be-
tween genotype and phenotype in SMA and to elucidate
the role of the cenSMN gene in modifying the severity
of the disease. Amore extensive telSMNmutation survey
also could have direct clinical utility; if common intra-
genic mutations are found in this population of SMA
patients who retain a copy of the telSMN gene, assays
for detection of these mutations can be designed to in-
crease the sensitivity of SMA molecular diagnosis.
The purpose of our study was to determine the fre-
quency, type, and distribution of intragenic telSMNmu-
tations and their relation to SMA phenotype. In this
article, we describe the results of screening for small
mutations in the entire coding region of the telSMN
gene, in a large population of patients referred for SMA
diagnostic testing. Our mutation-screening protocol in-
volved an initial quantitative PCR assay of telSMN copy
number, for identification of likely SMA compound
heterozygotes (individuals lacking one copy of telSMN
and having another mutation in their other copy), fol-
lowed by heteroduplex analysis for telSMN mutation
detection.
Patients and Methods
Patient Selection and DNA Isolation
A total of 414 patients, referred to the Ohio State
University (OSU) Molecular Pathology Laboratory for
diagnostic SMA testing, were analyzed, to identify po-
tential compound heterozygotes. These patients did not
necessarily conform to all clinical criteria defined by the
SMA consortium (Munsat and Davies 1992). A small
number of patient samples were collected for prior ge-
netic studies; these patients did meet the established di-
agnostic criteria for SMA. DNA from all patients was
isolated from peripheral venous blood, by use of a salt-
ing-out protocol (Miller et al. 1988).
telSMN Exon 7 Deletion Analysis
The presence or absence of telSMN exon 7 was de-
termined by use of a PCR-based protocol, described else-
where (Lefebvre et al. 1995; van der Steege et al. 1995),
in whichDraI restriction-enyzme digestion of SMNexon
7 PCR product allows the cenSMN and telSMN genes
to be distinguished.
telSMN and cenSMN Gene Dosage Analysis
In patients who retained at least one copy of telSMN,
the copy number of the telSMN and cenSMN genes was
determined by use of a quantitative PCR assay, as de-
scribed elsewhere (McAndrew et al. 1997). This assay
utilizes an exon of the cystic fibrosis transmembrane reg-
ulator (CFTR) gene as a standard, to determine the copy
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Table 1
PCR Primers Used for Heteroduplex Analysis of telSMN
EXON
SIZE
(bp)
PRIMER SEQUENCE (5′r3′)
Sense Antisense
1 189 GCCGGAAGTCGTCACTCTT GGGTGCTGAGAGCGCTAATA
2A 203 CTGATTAAACCTATCTGAACATG CGTATGTTATCAATTCCTTTCCA
2B 218 CTGTGCACCACCCTGTAACATG AAGGACTAATGAGACATCC
3 320 CGAGATGATAGTTTGCCCTC CTCATCTAGTCTCTGCTTCC
4 252 CACCCTTATAACAAAAACCTGC GAGAGGTTAAATGTCCCGA
5 314 TGAGTCTGTTTGACTTCAGG TATCAAATTGTATGTGAAAGCA
6 246 CTCCCATATGTCCAGATTCTCTT AAGAGTAATTTAAGCCTCAGACAG
7 245 AGACTATCAACTTAATTTCTGATC GTAAGATTCACTTTCATAATGCTG
number of the telSMN and cenSMN genes, and incor-
porates the use of two internal standards (SMN-IS and
CFTR-IS), to monitor the efficiency of the PCR reaction
and to ensure that equal amounts of target genomic
DNA are added to each tube. Since this test uses CFTR
as the standard for determining the telSMN copy num-
ber, the significant limitation imposed by use of the
cenSMN gene (for which the copy number varies, in both
patients and controls) as a reference is avoided.
Heteroduplex Analysis
Patient samples in which telSMN gene dosage analysis
revealed only a single copy of telSMN were subjected
to heteroduplex analysis. Each SMN coding exon (1,
2A, 2B, and 3–7) was amplified, by PCR, from genomic
DNA: the PCR primers used (table 1) were selected on
the basis of published intron/exon boundary sequences
(Bu¨rglen et al. 1996a) and the primer sequences kindly
provided by Dr. Judith Melki. The PCR reactions were
performed by use of 75 ng each of the appropriate sense
and antisense primers, in a 50-ml reaction mixture con-
taining 1 U Taq polymerase (Perkin-Elmer), 0.5 mM
dNTP, 3 mM MgCl2, and 5 ml 10# PCR buffer (670
mM Tris, 100 mM b-mercaptoethanol, 166 mM am-
monium sulfate, 67 mM EDTA, and 0.5 mg BSA/ml).
PCR cycling consisted of an initial denaturation step at
95C for 5 min, followed by 35 cycles of 95C for 1
min, 55C for 2 min, and 72C for 3 min, with a final
extension at 72C for 8 min. To allow heteroduplex for-
mation, PCR products were heated to 95C for 5 min
and then were incubated at 37C for 30 min. Fifteen
microliters of PCR product was mixed with 2.5 ml 6#
mutation detection–enhancement (MDE) gel loading
buffer (FMC) and then was electrophoresed on a 50-
cm-high, 0.8-mm-thick MDE gel (FMC), for 15 h at
1,000 V. The gel was stained in a solution of 0.6# Tris
borate–EDTA containing 1 mg ethidium bromide/ml and
then was photographed under ultraviolet light.
Subcloning and Sequencing
The PCR and reverse transcription–PCR (RT-PCR)
amplification products to be sequenced were subcloned
into the TA cloning vector (Invitrogen), in accordance
with the manufacturer’s instructions. Sequencing of plas-
mid DNA purified by use of Wizard Minipreps (Pro-
mega) was performed with the dsDNACycle Sequencing
System (Gibco BRL). Sequencing-reaction productswere
analyzed by use of a 5% denaturing polyacrylamide gel.
The gels were transferred onto blotting paper, dried, and
exposed to Hyperfilm-MP (Amersham) at 70C for
12–24 h. Mutations were sequenced on both DNA
strands, and multiple subclones were analyzed.
FokI Restriction-Enzyme Analysis of SMN Exon 1
Subclones
Exon 1 of the SMN gene was PCR amplified (table
1) from genomic DNA from patients with the A2G mis-
sense mutation and from controls and then was sub-
cloned into the TA cloning vector (Invitrogen). After
colony PCR of the exon 1 subclones, 18 ml of the re-
sulting 189-bp PCR product was digested with 4 U FokI
(New England Biolabs) for 2 h and was electrophoresed
on 12% polyacrylamide gels, for 400 V-h. Both the A2G
missense mutation and the CrT polymorphism 14 bp
upstream of exon 1 create FokI sites; FokI digestion
cleaves the 189-bp PCR product 79 bp from the 5′ end
in alleles with the A2G mutation and 32 bp from the 5′
end in alleles with the CrT polymorphism.
RNA Extraction and cDNA Synthesis
Total RNA was isolated from peripheral blood lym-
phocytes or from skeletal muscle, by use of TRIzol Re-
agent (Gibco BRL). First-strand cDNA synthesis was
performed with 2 mg RNA (based on spectrophotometric
quantitation) by use of oligo(dT) and Superscript II
Rnase H Reverse Transcriptase (200 U/ml; Gibco BRL),
in accordance with the manufacturer’s instructions.
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RT-PCR Confirmation of Variant SMN Sequences as
Telomeric
In order to determine whether the variant SMN se-
quences identified in SMA patients were contained with-
in the telSMN or cenSMN genes, RT-PCR analysis was
performed. The single-stranded cDNAs synthesized from
patient total RNA were PCR amplified, by use of sense
and antisense primers selected to encompass both the
variant sequence and the exon 7 and exon 8 single-base
changes between the telSMN and cenSMN genes, and
then were subcloned. These sequence changes allow the
centromeric and telomeric copies of exons 7 and 8 to
be differentiated by use of DraI (exon 7) or DdeI (exon
8) restriction-enzyme digestion (Lefebvre et al. 1995; van
der Steege et al. 1995). It then could be demonstrated,
by direct sequencing and/or restriction digestion of pa-
tient subclones, whether the variant SMN sequences
were exclusive to transcripts derived from telSMN or
from cenSMN.
For the A2G missense mutation, 75 ng each of sense
primer SMNaf (5′-TGC GCA TCC GCGGGT TTG CT-
3′) and antisense primer SMNcr (5′-TCA TTTAGTGCT
GCT CTA TGC CA-3′) were used to amplify patient
cDNA from exons 1–8, by means of reaction-mixture
components and PCR conditions identical to those used
for the heteroduplex analysis. The resulting RT-PCR
products then were subcloned into the TA cloning vector
(Invitrogen). Patient subclones containing telSMN exon
7 were identified by PCR andDraI digestion. These telo-
meric subclones were shown to contain the CrG trans-
version at position 38, by FokI digestion and electro-
phoresis on 12% polyacrylamide gels, demonstrating
that the A2G mutation occurs in the telSMN gene.
RT-PCR Analysis of the SMN Gene in a Potential SMA
Compound Heterozygote
Single-stranded cDNA synthesized from patient and
control lymphocyte total RNA was PCR amplified by
use of the following overlapping primer sets, selected to
span the SMN cDNA: (1) exons 1–3, sense primer
SMNaf (5′-TGC GCA TCC GCG GGT TTG CT-3′) and
antisense primer SMNar (5′-GAA CAT TTG TCC CCA
ACT TTC CA-3′); (2) exons 2B–4, sense primer SMNbf
(5′-AAA GCC AAA AGA AGA ATA CTG CAG-3′) and
antisense primer 541C460 (5′-GAG AAA GGA GTT
CCA TGG AGC AG-3′); (3) exons 4–8, sense primer
541C380 (5′-GTG AGA ACT CCA GGT CTC CTG G-
3′) and antisense primer SMNcr (5′-TCA TTTAGTGCT
GCT CTA TGC CA-3′); and (4) exons 6–8, sense primer
541C618 (5′-CTC CCA TAT GTC CAG ATT CTC TT-
3′) and antisense primer 541C1120 (5′-CTA CAA CAC
CCT TCT CAC AG-3′). RT-PCR reaction-mixture com-
ponents and cycling conditions were identical to those
used for the heteroduplex analysis. The resulting RT-
PCR products were electrophoresed on 12% polyacryl-
amide gels, stained with ethidium bromide, and pho-
tographed under ultraviolet light.
Semiquantitative RT-PCR Analysis of SMN Transcripts
The transcript of the hypoxanthine phosphoribosyl
transferase (HPRT) gene was used as an internal control,
to allow analysis and comparison of the SMN-transcript
levels of the samples. PCR primers 541C380 and
541C1120 were used for amplification of exons 4–8 of
the SMN gene, yielding four possible RT-PCR products
(derived from full-length SMN transcripts and isoforms
lacking exons 5 and/or 7). Primers for amplification of
HPRT (HPRTf, 5′-TGT AAT GAC CAG TCA ACAGG-
3′, and HPRTR1, 5′-ATT GAC TGC TTC TTA CTT
TTC T-3′) were selected to produce a product of a size
similar to (but distinguishably different from) the full-
length SMN transcript (Jolly et al. 1983). The two for-
ward primers (541C380 and HPRTf) were end labeled
with g[32P]-ATP (10 mCi/ml; Amersham). Twomicroliters
of cDNA (equivalent to 0.2 mg total RNA) was ampli-
fied, by PCR, in a 25-ml reaction mixture containing 0.5
mM dNTP, 1 U Taq polymerase (Perkin-Elmer), 30 ng
of each SMN primer, 7.5 ng of each HPRT primer, 2.5
mM MgCl2, and 2.5 ml 10# PCR buffer. Cycling con-
ditions consisted of an initial denaturation step at 95C
for 5 min, followed by 20 cycles of 95C for 1 min, 55C
for 2 min, and 72C for 3 min, with a final extension
step at 72C for 8 min. Ten microliters of the resulting
PCR products was combined with 5 ml loading dye (95%
formamide, 10 mM EDTA, 0.1% bromophenol blue,
and 0.1% xylene cyanol) and was electrophoresed on a
6% denaturing polyacrylamide gel. The gel was dried
and exposed to Hyperfilm-MP (Amersham) for 1–3 d.
Densitometry of the bands was performed on a Shi-
madzu CS-9000, and the ratios between the amounts of
the SMN isoforms and the HPRT transcripts were de-
termined for all samples. Each sample was assayed in
duplicate.
Ag1-CA Genotyping
PCR primers and reaction conditions used for ampli-
fication of the Ag1-CA microsatellite repeat sequence
were as described elsewhere (DiDonato et al. 1994).
Results
Over a period of 4 years (1995–98), samples from
414 individuals were sent to our laboratory for molec-
ular diagnosis of SMA. Of these patients, 206 (49.8%)
were found to be homozygously lacking telSMN exon
7, by means of the standard PCR-based assay (Lefebvre
et al. 1995; van der Steege et al. 1995). The remaining
208 “nondeletion” patients were screened for small
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Figure 1 Distribution of reported intragenic telSMN mutations. Mutations identified in the 11 OSU patients (and the resulting SMA
phenotypes) are drawn above the telSMN coding region. The S262I and T274I mutations also were reported by Hahnen et al. (1997). SIP1
and Sm protein-binding sites, as well as the SMN oligomerization domain (denoted “SMN”), are indicated by straight lines under the gene.
The region of telSMN exons 6 and 7 is shown in greater detail at the bottom of the figure. Refer to table 2 for the authorship of specific
mutations.
telSMNmutations, by use of a protocol of initial telSMN
gene dosage analysis followed by heteroduplex analysis.
Dosage analysis of the telSMN gene revealed that 23
(11.1%) of these 208 nondeletion patients possessed
only a single copy of the telSMN gene, making them
likely compound heterozygotes (patients with one
telSMN gene lost to deletion or sequence conversion and
one telSMN gene containing another type of mutation).
For these 23 patients, the entire telSMN coding region
was screened for small mutations, by heteroduplex anal-
ysis. Thus far, five intragenic telSMN mutations have
been identified in 11 (47.8%) of these 23 patients (fig.
1 and table 2). Four of the mutations have been de-
scribed previously by our group and by others; two mis-
sense mutations, S262I (Hahnen et al. 1997; McAndrew
et al. 1997) and T274I (Hahnen et al. 1997), have been
found in one patient each, and two frameshiftmutations,
800ins11 (Parsons et al. 1996) and 542delGT (Parsons
et al. 1998), have been identified in four unrelated pa-
tients and in two unrelated patients, respectively (nucle-
otide positions were numbered as in the study by Le-
febvre et al. [1995]).
We now report the most 5′ intragenic telSMN mu-
tation identified to date—a missense mutation (A2G)
that results in the replacement of alanine by glycine in
the second codon of the telSMN gene. Heteroduplex
analysis of SMN exon 1, PCR amplified from genomic
DNA from three unrelated patients (two with type III
SMA and one with type II SMA), demonstrated abnor-
mal patterns. Sequence analysis of patient exon 1 sub-
clones revealed a CrG transversion at nucleotide 38,
producing a substitution of glycine for alanine (A2G) at
a residue, in the deduced SMN protein, that is conserved
in zebra fish (A.H.M.B., unpublished data). This base
change produces a FokI restriction-enzyme site within
exon 1 of the SMN gene, allowing other individuals to
be screened easily for the CrG transversion, by exon 1
PCR and FokI digestion. The nucleotide change was not
observed in 200 normal chromosomes. In order to de-
termine whether the variant exon 1 sequence was con-
tained within the telomeric or centromeric copy of the
SMN gene, patient lymphocyte RNA was amplified by
RT-PCR, using an exon 1 sense primer and an exon 8
antisense primer, and then was subcloned. Patient sub-
clones containing telSMN exon 7were identified byDraI
restriction-enzyme digestion; FokI restriction-enzyme
analysis of exon 1 of these telomeric subclones revealed
that the mutant transcripts were derived from telSMN.
Interestingly, all three patients with the A2G missense
mutation also had a CrT polymorphism in the telSMN
gene, 14 bp upstream of exon 1. This polymorphism,
which also creates a FokI cleavage site, was found in
only 3 of 100 control individuals tested. In order to
determine whether the A2G mutation and the 5′ UTR
polymorphism were on the same telSMN allele, exon 1
subclones both from controls and from A2G patients
were amplified by colony PCR and were subjected to
FokI restriction-enzyme digestion. The FokI digestion
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Table 2
Summary of Small Mutations in the telSMN Gene
Mutation Location Nucleotide Change Effect on Translation SMA Type Reference
1 Exon 1 38 CrG AlarGly (A2G) II, III This study
2 Exon 3 430 del 4 Frameshift I, II, III Bussaglia et al. 1995
3 Exon 3 472 del 5 Frameshift I Brahe et al. 1996
4 Exon 4 542 del GT Frameshift I, II Parsons et al. 1998
5 Exon 6 767 CrT ProrLeu (P245L) III Rochette et al. 1997
6 Exon 6 800 ins 11 Frameshift I, II Parsons et al. 1996
7 Exon 6 818 GrT SerrIle (S262I) III Hahnen et al. 1997; Mc-
Andrew et al. 1997
8 Exon 6 848 ArG TyrrCys (Y272C) I Lefebvre et al. 1995; Rochette
et al. 1997
9 Exon 6 854 CrT ThrrIle (T274I) II, III Hahnen et al. 1997; this study
10 Exon 6 856 GrA GlyrSer (G275S) III Bu¨rglen et al. 1996b
11 Intron 6 868-10 del 7 Splicing defect? ) Lefebvre et al. 1995
12 Exon 7 869 GrT GlyrVal (G279V) I Talbot et al. 1997
13 Intron 7 9214 del 4 Splicing defect? ) Lefebvre et al. 1995
Figure 2 FokI restriction-enzyme analysis of SMN exon 1 sub-
clones. Lane 1, Uncut 189-bp exon 1 colony-PCR product. Lanes 2–4,
Colony-PCR products digested with FokI. The control subclone in lane
2 does not contain either the mutation or the polymorphism and,
consequently, was not cut by FokI. The control subclone in lane 3 has
the polymorphism and was cleaved into 32-bp and 157-bp fragments.
An A2G-patient subclone is present in lane 4; as with the other two
A2G patients, the polymorphism is present on the same SMN allele
as the point mutation, resulting in fragments of 32, 47, and 110 bp
after FokI digestion. Lane MW, FX174/HaeIII molecular-weight
marker. Bands representing sizes of 234, 194, 118, and 72 bp are
labeled.
products then were electrophoresed on 12% polyacryl-
amide gels (fig. 2). FokI digestion cleaves the full-length
189-bp exon 1 PCR product 79 bp from the 5′ end in
alleles with the A2G mutation and 32 bp from the 5′
end in alleles with the CrT polymorphism. In all three
SMA patients with the A2G missense mutation, FokI
digestion and PAGE revealed fragments of 32, 47, and
110 bp, confirming that both the mutation and the poly-
morphism are present on the same telSMN allele and
providing evidence for a founder chromosome for this
mutation. In order to further investigate the possibility
that these intragenic telSMN mutations occur on com-
mon genetic backgrounds, Ag1-CA genotyping (Di-
Donato et al. 1994) was performed on our patients with
the A2G, 800ins11, and 542delGT mutations. These
family studies were hampered by the fact that limited
DNA samples were available from other related indi-
viduals; however, each of these three intragenic telSMN
mutations appeared to be found on common Ag1-CA
alleles. Although incomplete, this Ag1-CA marker data
supports an ancestral origin for the 800ins11 and
542delGT frameshift mutations, as well as for the A2G
missense mutation.
Although only a relatively small number of intragenic
telSMN mutations have been identified, many of them
have now been found in multiple unrelated SMA pa-
tients. All five telSMN mutations identified in our SMA
patient population have now been found in more than
one individual (fig. 1). Three of the mutations have been
identified more than once in our OSU patient popula-
tion: the A2Gmissense mutation has been found in three
patients, 800ins11 in four patients, and 542delGT in
two patients. Although seen only once in our patients,
the two other missense mutations, S262I and T274I,
have been identified in another laboratory (Hahnen et
al. 1997). The intragenic mutations identified thus far
cluster at the 3′ end of the telSMN gene; of the five
mutations identified in our patient population, three oc-
cur within exon 6 (fig. 1). In fact, 9 of the 13 small
telSMN mutations identified by us and by others occur
in exons 6 and 7 of the gene; other than the A2G
missense mutation described in this article, only frame-
shift mutations have been identified upstream of exon 6
(table 2).
As a result of not finding intragenic telSMNmutations
in 12 of 23 SMA-like individuals with a single copy of
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Figure 3 Semiquantitative RT-PCR analysis of SMN transcripts.
The HPRT RT-PCR product is present at the top of the gel, with
products amplified from full-length SMN transcripts (SMNfull) and the
SMN isoform lacking exon 7 (SMNex7) below. Lanes 1 and 6, Normal
controls (SMNfull/HPRT ratios of 0.74 and 2.45, respectively). Lane
2, Patient with type II SMA who homozygously lacks telSMN. Lanes
3 and 4, SMA patients with telSMNmissense mutations A2G (SMNfull/
HPRT ratio of 1.76) and S262I (SMNfull/HPRT ratio of 0.28), re-
spectively. Lane 5, Potential SMA compound heterozygote in whom
no telSMN mutation has been identified (SMNfull/HPRT ratio of 0.89).
telSMN, we decided to pursue further studies at the
RNA level. Some types of telSMN mutations, such as
intronic variations affecting telSMN splicing and whole-
exon duplications or deletions in telSMN, would be
missed by our screening protocol using heteroduplex
analysis of the SMN coding region; one method of
screening for these other types of mutations is by RT-
PCR analysis of SMN transcripts. In 1 of our 12 po-
tential SMA compound heterozygotes without an iden-
tified telSMN mutation (patient 7620), lymphocyte
RNA was amplified by RT-PCR using primers spanning
the SMN transcript and was electrophoresed on 12%
polyacrylamide gels. The resulting RT-PCR band pat-
terns were identical to those found in normal controls;
no abnormally sized SMN transcripts were identified,
and no SMN isoforms were found to be absent. Unfor-
tunately, RNA is currently unavailable from the other
potential compound heterozygotes; thus, these individ-
uals have not yet been screened in this manner.
In addition, mutations in the telSMN promoter region
or in other sequences affecting transcription of the
telSMN gene could account for ∼50% of the potential
SMA compound heterozygotes in whom no telSMNmu-
tation was found by heteroduplex analysis. In order to
investigate this possibility, semiquantitative RT-PCRwas
performed on patient 7620, as well as on SMA patients
and normal controls (fig. 3). This RT-PCR assay used
the transcript of the HPRT gene as an internal control,
to allow analysis and comparison of the SMN-transcript
levels of the samples. PCR primers located within exons
4–8 of the SMN gene were used to amplify four possible
RT-PCR products (derived from full-length SMN tran-
scripts and from isoforms lacking exon 7, exon 5, or
both exons 5 and 7); primers selected to amplify the
HPRT transcript were included in the same PCR reac-
tion. Densitometry of the resulting bands was per-
formed, and the ratios between the amounts of the SMN
isoforms and the HPRT transcripts were determined. By
use of this assay, potential SMA compound heterozygote
7620 (fig. 3, lane 5) was not found to have a significantly
reduced amount of full-length telSMN transcript
(SMNfull/HPRT transcript ratio of 0.89), providing no
support for the theory that this patient might have a
mutation-altering transcription of the telSMN gene.
Polymorphisms in the SMN promoter region have been
shown to alter expression of the SMN gene (U. R. Mon-
ani, personal communication), which might explain the
large difference in levels of full-length SMN transcripts,
between our two normal controls (fig. 3, lanes 1 and 6),
who have SMNfull/HPRT ratios of 0.74 and 2.45. This
assay also appears to indicate that the two missense mu-
tations A2G and S262I work by different pathogenic
mechanisms. The patient with the A2G mutation has a
large amount of full-length SMN transcript (SMNfull/
HPRT ratio of 1.76), indicating that the mutation’s del-
eterious effect might be occurring at the protein level.
In contrast, the patient with the S262I mutation has a
reduced amount of full-length SMN mRNA (SMNfull/
HPRT ratio of 0.28), raising the possibility that this
mutation causes its damage at the level of transcription.
The S262I mutation has been demonstrated to result in
reduced SMN self-association (Lorson et al. 1998).
Attempts to correlate intragenic telSMN mutations
with SMA phenotypes are complicated by the effect of
the other telSMN allele, which may be either deleted or
converted. Despite this fact, several preliminary conclu-
sions regarding SMA genotype-phenotype correlation
can be drawn from our patients with small telSMN mu-
tations. In our patients, telSMN missense mutations ap-
pear to be associated with relatively mild SMA pheno-
types; the A2G mutation was found in two patients with
type III SMA and in one patient with type II SMA, and
the S262I and T274I mutations were each identified in
a patient with type III SMA. In contrast, frameshift mu-
tations in telSMN were found in much more severely
affected patients; the 800ins11 mutation was found in
three patients with type I SMA and in one patient with
type II SMA, and the 542delGT mutation was present
in one patient with type I SMA and in one patient with
type II SMA. In SMA patients who homozygously lack
the telSMN gene, the cenSMN gene copy number has
been demonstrated to be correlated with SMA pheno-
type: an increased number of copies of cenSMN—which
can occur as a result of gene conversion events, from
telSMN to cenSMN—is more often associated with a
mild SMA phenotype (Burghes 1997; Campbell et al.
1997; DiDonato et al. 1997; McAndrew et al. 1997).
Analysis of cenSMN copy number in our patients with
frameshift mutations provides support for this theory:
with regard to mutations 800ins11 and 542delGT, pa-
tients with an increased cenSMN copy number had sig-
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Table 3
Relationship between cenSMN Copy Number and SMA Phenotype
in Patients with Frameshift telSMN Mutations
TelSMN Mutation
and Patient Number
No. of
CenSMN Copies
SMA
Type
800ins11:
4756 2 I
4961 2 I
5749 2 I
7023 3 II
542delGT:
5954 2 I
7056 3 II
nificantly less severe SMA phenotypes (table 3). Of the
four patients with the 800ins11 mutation, three had two
copies of cenSMN and were very severely affected (type
I SMA); the fourth individual had three copies of
cenSMN and was more mildly affected (type II SMA).
Similarly, with regard to the 542delGT mutation, the
patient with type I SMA had two copies of cenSMN,
and the patient with type II SMA had three copies of
cenSMN. The cenSMN–copy number data from our
three patients with the A2G missense mutation were not
informative; all three individuals possess a single copy
of the cenSMN gene.
Discussion
Frequency of Intragenic telSMN Mutations
Of the 414 patients referred to our laboratory for
diagnostic SMA testing, 206 (49.8%) were found to be
homozygously lacking telSMN exon 7 and were given
a positive molecular diagnosis of SMA. For the remain-
ing 208 patients (50.2%), a quantitative PCR assay for
determination of telSMNgene copy number (McAndrew
et al. 1997) was performed. In addition to allowing the
molecular diagnosis of SMA carriers, this test also en-
ables us to efficiently screen patients with SMA-like clin-
ical symptoms, in order to help distinguish SMA com-
pound heterozygotes from non-5q cases (Rochette et al.
1997). Since telSMN is homozygously absent in ∼95%
of 5q SMA cases, almost all of the remaining 5q SMA
individuals should be compound heterozygotes (lacking
one copy of telSMN and having a different mutation in
their remaining copy of the gene), according to Hardy-
Weinberg equilibrium. Once an SMA-like patient with
one copy of the telSMN gene has been identified, the
probability of a 5q SMA diagnosis is increased signifi-
cantly. However, it is still possible that the individual
may be an SMA carrier whose symptoms are caused by
another neuromuscular disorder. We therefore used het-
eroduplex analysis for mutation screening of the re-
maining copy of telSMN. By use of this initial quanti-
tative screen for telSMN gene copy number, the number
of patients who require mutation analysis can be reduced
drastically; we conducted heteroduplex analysis only on
the 23 patients (11.1%) who were found to have a single
copy of telSMN, instead of on all 208 deletion-negative
individuals. For the remaining 185 (88.9%) of these 208
deletion-negative SMA-like patients, the telSMN gene
dosage is normal, and 5q SMA is effectively ruled out
as a diagnosis; for these cases, the physician should con-
sider other neuromuscular diseases. This telSMN gene
dosage–based screening strategy would not be as useful
in the diagnosis of SMA in consanguineous families or
in groups exhibiting a significant founder effect, since
individuals who are homozygous for a nondeletion
telSMN mutation would be more common among those
groups (Bussaglia et al. 1995). If we consider the 23
patients analyzed as having a positive molecular diag-
nosis of 5q SMA, then 206 (90%) of 229 SMA-positive
patients in our population were homozygously lacking
telSMN exon 7, whereas 23 (10%) of 229 patients were
compound heterozygotes. Various studies have deter-
mined the proportion of SMA patients who homozy-
gously lack telSMN (as a result of either deletion or
sequence conversion) to be ∼95% (Cobben et al. 1995;
Hahnen et al. 1995, 1996; Lefebvre et al. 1995; Ro-
drigues et al. 1995; van der Steege et al. 1996; Velasco
et al. 1996; DiDonato et al. 1997); our numbers are in
approximate agreement with this data, especially in view
of the possibility that some of these 23 individuals with
one copy of telSMN are SMA carriers with another neu-
romuscular disease.
By use of heteroduplex analysis, telSMN mutations
were identified in 11 (47.8%) of 23 possible compound
heterozygotes. There are many possible reasons to ex-
plain why telSMN mutations were not identified in the
other 12 patients: (1) some of these individuals may be
carriers of a telSMN-deleted or -converted allele and
may not be actual SMA patients; (2) the promoter and
3′ UTR regions were not analyzed extensively; (3) in-
tronic sequences may play a significant role in disease
expression; (4) whole-exon duplications or deletions
would not be detected by heteroduplex analysis; and (5)
heteroduplex analysis does not have 100% sensitivity in
screening for sequence variations. Although telSMNmu-
tations were found only in approximately half of the
patients with a single copy of telSMN, the detection rate
varied dramatically by SMA phenotype: mutations were
identified in all four individuals with type I SMA (three
of whom had the 800ins11 mutation) but in only 7
(36.8%) of the 19 patients withmilder SMAphenotypes.
Since whole-exon mutations would not be predicted to
disrupt the translational reading frame, they could pro-
duce a mild SMA phenotype; similarly, intronic muta-
tions affecting telSMN transcript splicing also could al-
low some telSMN protein function. Perhaps the lower
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telSMN mutation–detection rate for patients with type
II or type III SMA can be explained by the presence of
these types of mutations. One method for investigation
of the possibility of whole-exon deletions or duplica-
tions, as well as of mutations that affect splicing, is to
look for abnormal SMN transcripts, by use of RT-PCR.
Unfortunately, RNA was available from only 1 of the
12 possible SMA compound heterozygotes in whom no
telSMN mutation was identified; RT-PCR analysis using
primers spanning the SMN gene failed to reveal any
abnormally sized transcripts in this individual. Simi-
larly, semiquantitative RT-PCR was used to determine
whether this potential compound heterozygote had a
reduced amount of full-length SMN transcript in lym-
phocytes; however, the patient had a significant amount
of full-length transcript, suggesting that the pathogenic
mechanism for his telSMN mutation (if one is present)
is not at the level of transcription.
Type and Distribution of Small telSMN Mutations
To date, a total of 13 small mutations in the telSMN
gene have been reported (fig. 1 and table 2), including
four frameshift mutations (Bussaglia et al. 1995; Brahe
et al. 1996; Parsons et al. 1996, 1998), seven missense
mutations (Lefebvre et al. 1995; Bu¨rglen et al. 1996b;
Hahnen et al. 1997; McAndrew et al. 1997; Rochette
et al. 1997; Talbot et al. 1997; this study), and two small
deletions in consensus splice donor/acceptor sites (Le-
febvre et al. 1995). Although only a relatively small num-
ber of intragenic telSMNmutations have been identified,
many of them have now been found in more than one
SMA patient. All five of the telSMNmutations identified
in our SMA patient population have now been found in
multiple unrelated individuals; similarly, several other
intragenic telSMN mutations have been reported by
more than one laboratory (Lefebvre et al. 1995; Hahnen
et al. 1997; McAndrew et al. 1997; Rochette et al. 1997;
this study). Our data support the possibility of an an-
cestral origin for the three mutations identified in more
than one individual in our patient population; all three
patients with the A2G missense mutation were found to
have a rare (∼3% of normals) 5′ UTR polymorphism on
the same allele as that of the mutation (fig. 2). In ad-
dition, Ag1-CA microsatellite-marker data also supports
the possibility of founder chromosomes for the 800ins11
and 542delGT frameshift mutations, as well as for the
A2G missense mutation. In our SMA patients in whom
both telSMN mutations have been identified (either in-
dividuals homozygously lacking telSMN or compound
heterozygotes with a defined intragenic mutation), the
allele frequencies for the 800ins11 and A2G mutations
are ∼1% (4 of 434 chromosomes) and ∼0.7% (3 of 434
chromosomes), respectively. Although diagnostic screen-
ing could be implemented easily to test for these mu-
tations, as is done routinely for rare cystic fibrosis mu-
tations, the additional requirement of testing for telSMN
gene dosage, by quantitative PCR, makes this screening
strategy less feasible.
Because most SMA patients are homozygously lacking
telSMN, characterization of the relatively rare intragenic
telSMN mutations is valuable for identification of im-
portant functional domains of the gene. The group of
telSMN mutations identified to date strongly suggest
that the 3′ end of the gene is essential for telSMN func-
tion (fig. 1); except for the A2G missense mutation, all
of the nonframeshift mutations identified in telSMN
cluster within exons 6 and 7. Recent evidence supports
a role for SMN in snRNP biogenesis and function (Liu
and Dreyfuss 1996; Fischer et al. 1997; Liu et al. 1997).
Immunofluorescence studies using a monoclonal anti-
body to the SMN protein have revealed that the SMN
protein is localized to novel nuclear structures called
“gems,” which display similarity to and possibly interact
with coiled bodies, which are thought to play a role in
the processing and metabolism of small nuclear RNAs
(snRNAs) (Liu and Dreyfuss 1996). The region of the
SMN protein encoded by exon 2 has been shown to be
necessary and sufficient for nucleic acid binding (Lorson
and Androphy 1998). The SMN protein has been found
to be tightly associated with the novel protein SIP1
(SMN-interacting protein 1), within a complex that also
contains several spliceosomal snRNP proteins (Liu et al.
1997). In addition, in a Xenopus oocyte model, anti-
bodies directed against this complex have been shown
to block both the assembly of the Sm class of snRNP
proteins by spliceosomal snRNAs and the nuclear im-
port of the snRNP complex (Fischer et al. 1997), pro-
viding additional evidence for the proposed biological
role of the SMN protein in snRNP biogenesis and func-
tion. The SMN protein has been found to contain two
separate binding sites for the Sm proteins and SIP1; the
Sm protein binding site is located within the conserved
carboxy terminus of the SMN protein (amino acids
240–267), which corresponds to the 5′ end of exon 6,
at the DNA level (fig. 1). Three of the intragenic telSMN
mutations (P245L, 800ins11, and S262I) identified to
date occur within this domain (Parsons et al. 1996;
McAndrew et al. 1997; Rochette et al. 1997); however,
the other six missense and consensus splice-site muta-
tions occurring in exons 6 and 7 are located farther
downstream. A recent study (Lorson et al. 1998) has
defined a 30–amino acid region, farther toward the 3′
end of exon 6 (amino acids 249–278), that is essential
for oligomerization of the SMN protein (fig. 1). Several
of the missense telSMN mutations (S262I, Y272C,
T274I, and G279V) were shown to result in extremely
inefficient self-association; furthermore, a direct corre-
lation between impairment of oligomerization capability
and severity of SMA phenotype was demonstrated (Lor-
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son et al. 1998). Except for the novel A2G mutation,
all telSMN missense mutations reported to date cluster
within or immediately adjacent to this oligomerization
domain. The only missense mutation identified outside
this region is the A2G mutation, which occurs closely
upstream from the SIP1 binding site, at amino acids
13–44 (Liu et al. 1997). It is possible that this substi-
tution sufficiently disrupts the conformation of the SMN
protein to alter SIP1 binding; the replacement of alanine
by glycine has been shown to have a significant desta-
bilizing effect on peptide a-helical structure (Lyu et al.
1990; Chakrabartty et al. 1991).
Genotype-Phenotype Correlation
Since ∼95% of SMA patients are homozygously lack-
ing exon 7 of the telSMN gene, regardless of clinical
phenotype (Lefebvre et al. 1995), genotype-phenotype
correlation for SMA has not been straightforward.How-
ever, additional research has shown that all losses of
telSMN exon 7 are not equal; deletions of telSMN are
more common in severely affected patients with type I
SMA, whereas gene conversions between the telSMN
and cenSMN genes are associated with a milder disease
phenotype (Burghes 1997; Campbell et al. 1997; Di-
Donato et al. 1997; McAndrew et al. 1997; Simard et
al. 1997). The assignment of specific intragenic telSMN
mutations to disease phenotypes is complicated by the
effect of these different types of lost telSMN allele. Ge-
notype-phenotype correlation for SMA also has been
demonstrated at the protein level: the reduction of SMN
protein in patients has been found to be directly cor-
related with the severity of the SMA phenotype (Coovert
et al. 1997; Lefebvre et al. 1997). Within our patient
population, frameshift telSMN mutations appear to
cause more-severe SMA phenotypes (types I and II) than
do missense mutations (types II and III). However, a
number of exceptions to this rule have been reported by
other groups; the 432del4 frameshift mutation has been
found in Spanish SMA patients of all three clinical types
(some of them consanguineous), and the missense mu-
tations Y272C and G279V have been found in severely
affected patients with type I SMA.
The characterization of these intragenic telSMN mu-
tations has provided additional information regarding
the potential role of the cenSMN gene in modifying the
SMA phenotype. An increased cenSMN copy number
(which can be found as a result of sequence conversion
of telSMN to cenSMN) has been reported to be corre-
lated with a milder disease phenotype in patients who
are homozygously lacking telSMN (Burghes 1997;
Campbell et al. 1997; DiDonato et al. 1997; McAndrew
et al. 1997). Analysis of cenSMN copy number in our
patients with frameshift mutations demonstrates that
this cenSMN gene dosage effect also occurs in SMA
compound heterozygotes; with regard to both recurring
frameshift mutations (800ins11 and 542delGT), patients
with increased cenSMN copy number had significantly
less severe SMA phenotypes (table 3). The idea that the
cenSMN gene can act in a compensatory manner, to
modify the SMA phenotype, is particularly intriguing as
a basis for a potential therapeutic strategy; perhaps tech-
niques will be developed to manipulate expression of the
cenSMN gene, as a means of replacing an absent or
defective telSMN gene.
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